On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...

Dividend investing is an excellent strategy for (at least) two reasons. Here are two companies that can pull it off: Amgen ...

The ongoing investigation by Wyden and his Democratic compatriots from the Finance Committee has pointed the finger at ...

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

Senator Ron Wyden (D-Ore.), a senior member of the Senate Finance Committee, accused Pfizer (PFE) of carrying out what he ...

The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...

Sen. Ron Wyden and other Democrats claim Pfizer used a "colossal" scheme to avoid paying billions in U.S. taxes.